






- (51) International Patent Classification:
C07J 63/00 (2006.01) *A61P 31/18* (2006.01)
A61K 31/56 (2006.01)
- (21) International Application Number:
PCT/US2012/022852
- (22) International Filing Date:
27 January 2012 (27.01.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/437,893 31 January 2011 (31.01.2011) US
- (71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

- (72) Inventors; and
(75) Inventors/Applicants (for US only): **REGUEIRO-REN, Alicia** [ES/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **LIU, Zheng** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SWIDORSKI, Jacob** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SIN, Ny** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **VENABLES, Brian Lee** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **SIT, Sing-Yuen** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **CHEN, Yan** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **CHEN, Jie** [CN/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

[Continued on next page]

- (54) Title: C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY



(57) Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III. These compounds are useful for the treatment of HIV and AIDS.



(US). **MEANWELL, Nicholas A.** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

(74) **Agents:** **LEVIS, John F.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*